The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective
Organic Process Research & Development · 21.08.2026 · 30 (8) · 2136-2148
DOI: 10.1021/acs.oprd.6c00218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 17.07.2026. Verfasst von Joseph M. Bateman und 6 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Discovery Process Chemistry (DPC) has emerged as a critical bridge between discovery chemistry and chemical development that allows more seamless progression of drug candidates to the clinic. DPC aims to accelerate projects by integrating SAR-enabling methodologies, scalable route design to inform later campaigns, and early material delivery. Case studies from MSD, Johnson & Johnson, and AstraZeneca highlight how this model can drive innovation and mitigate risks at the interface between medicinal and process chemistry groups. Keywords: discovery process, route scouting, early scale-up, and SAR enabling.
Zitieren
APA
Bateman, J. M., Hughes, J. M. E., Jouffroy, M., Lindsay-Scott, P. J., McGuire, T. M., Valette, D., & Weinmann, H. (2026). The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective. Organic Process Research & Development, 30(8), 2136-2148. https://doi.org/10.1021/acs.oprd.6c00218
Vancouver
Bateman JM, Hughes JME, Jouffroy M, Lindsay-Scott PJ, McGuire TM, Valette D, et al. The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective. Organic Process Research & Development. 2026;30(8):2136-2148. doi:10.1021/acs.oprd.6c00218
BibTeX
@article{Bateman2026,
author = {Bateman, Joseph M. and Hughes, Jonathan M. E. and Jouffroy, Matthieu and Lindsay-Scott, Peter J. and McGuire, Thomas M. and Valette, Damien and Weinmann, Hilmar},
title = {The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective},
journal = {Organic Process Research & Development},
year = {2026},
volume = {30},
number = {8},
pages = {2136--2148},
doi = {10.1021/acs.oprd.6c00218}
}
EUVIMED